BBSRC-funded researchers at the University of East Anglia studied the effect in mice of consuming feed enriched with oil from glasshouse grown genetically engineered Camelina sativa, developed at the Rothamsted Research.
The goal of the research was to discover whether mammals (using mice as a model) can absorb and accumulate EPA from this novel source of omega-3s.
The team examined levels of EPA in various organs in the body such as the liver, as well as its effect on the expression of genes key for regulating the way the body processes fats. The results show that the benefits were similar to those derived from fish oils.
Lead researcher Prof Anne-Marie Minihane, from UEA’s Norwich Medical School, said: “The long chain omega-3 polyunsaturated fatty acid EPA is beneficial for cardiovascular and cognitive health, as well as for foetal development in pregnancy.
“The recommended minimum dietary intake can be achieved by eating one to two portions of oily fish per week.
“But for everyone in the world to achieve their minimum dietary intake, you would need around 1.3 million metric tonnes of EPA per year. Fish currently provide around 40 per cent of the required amount – so there is a large deficit between supply and demand.
“There is a great need to identify alternative and sustainable sources of these beneficial fatty acids.
“We wanted to test whether oil from genetically modified plants could be used as a substitute. This first study indicates that mammals can efficiently accumulate the key health-beneficial omega-3 fatty acid EPA.”
The research team studied mice, which had been fed with EPA oil from genetically engineered Camelina sativa, commonly known as false flax, but actually a member of the Brassicaceae family. Crops were grown in glasshouses at Rothamsted Research.
The researchers looked to see whether consuming oil from the engineered plants was as beneficial as EPA-rich fish oil. They did this by testing tissue concentrations of fatty acids in liver, muscle and brain tissue, along with the expression of genes involved in regulating EPA status and its physiological benefits.
Prof Minihane said: “The mice were fed with a control diet similar to a Westernised human diet, along with supplements of EPA from genetically engineered Camelina sativa or fish oil, for ten weeks – enough time for any beneficial results to be seen.
“We found that the genetically engineered oil is a bioavailable source of EPA, with comparable benefits for the liver to eating oily fish.”
The research was funded by BBSRC as part of an ongoing research programme to examine the sources and sustainability of omega-3 fatty acids, as well as their impact on health and risk of chronic disease. The novel Camelina oil used was produced as part of the BBSRC-funded Designing Seeds Institute Strategic Programme Grant to Rothamsted Research.
The study was reviewed and approved by the Animal Welfare and Ethical Review Body (AWERB) and was conducted within the provisions of the Animals (Scientific Procedures) act 1986.
More information can be found here: http://www.bbsrc.ac.uk/news/health/2016/160121-pr-fatty-acids-from-crops-could-replace-fish-oil/